Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Cited In for PubMed (Select 11877472)

1.

Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.

Sinha S, Crawford MP, Ortega SB, Karandikar NJ.

J Mult Scler (Foster City). 2015 Jan;2(1). pii: 1000130.

PMID:
26137595
2.

The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Ireland SJ, Guzman AA, O'Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL.

JAMA Neurol. 2014 Nov;71(11):1421-8. doi: 10.1001/jamaneurol.2014.1472.

3.

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.

Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):232-5. doi: 10.1016/j.jneuroim.2014.08.624. Epub 2014 Sep 2.

4.

How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Reder AT, Feng X.

J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158. Review.

PMID:
25084175
5.

Immune regulation of multiple sclerosis by CD8+ T cells.

Sinha S, Itani FR, Karandikar NJ.

Immunol Res. 2014 Aug;59(1-3):254-65. doi: 10.1007/s12026-014-8529-9. Review.

PMID:
24845461
6.

Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.

Cusick MF, Libbey JE, Trede NS, Fujinami RS.

PLoS One. 2014 Apr 9;9(4):e94486. doi: 10.1371/journal.pone.0094486. eCollection 2014.

7.

CD8(+) T cells in multiple sclerosis.

Denic A, Wootla B, Rodriguez M.

Expert Opin Ther Targets. 2013 Sep;17(9):1053-66. doi: 10.1517/14728222.2013.815726. Epub 2013 Jul 6. Review.

8.

CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.

Tyler AF, Mendoza JP, Firan M, Karandikar NJ.

PLoS One. 2013 Jun 21;8(6):e66772. Print 2013.

9.

The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis.

Ortega SB, Kashi VP, Tyler AF, Cunnusamy K, Mendoza JP, Karandikar NJ.

J Immunol. 2013 Jul 1;191(1):117-26. doi: 10.4049/jimmunol.1300452. Epub 2013 Jun 3.

10.

Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.

Fernández O.

J Cent Nerv Syst Dis. 2012 Aug 29;4:117-33. doi: 10.4137/JCNSD.S8755. Print 2012.

11.

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.

Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, Karandikar NJ.

Clin Immunol. 2013 May;147(2):105-19. doi: 10.1016/j.clim.2013.02.015. Epub 2013 Mar 6.

12.

What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Buzzard KA, Broadley SA, Butzkueven H.

Int J Mol Sci. 2012 Oct 4;13(10):12665-709. doi: 10.3390/ijms131012665. Review.

13.

IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn-/- mice.

Gutierrez T, Mayeux JM, Ortega SB, Karandikar NJ, Li QZ, Rakheja D, Zhou XJ, Satterthwaite AB.

Eur J Immunol. 2013 Feb;43(2):382-93. doi: 10.1002/eji.201142095. Epub 2012 Dec 18.

14.

The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Hestvik AL.

Toxins (Basel). 2010 Apr;2(4):856-77. doi: 10.3390/toxins2040856. Epub 2010 Apr 22. Review.

15.

Glatiramer acetate treatment increases stability of spinal synapses and down regulates MHC I during the course of EAE.

Scorisa JM, Freria CM, Victorio SC, Barbizan R, Zanon RG, Oliveira AL.

Int J Biol Sci. 2011;7(8):1188-202. Epub 2011 Oct 27.

16.

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M.

Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.

17.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

18.

Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis.

Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ.

J Neuroimmunol. 2011 May;234(1-2):131-40. doi: 10.1016/j.jneuroim.2011.02.001. Epub 2011 Mar 11.

19.

Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis.

Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM, Karandikar NJ.

J Autoimmun. 2011 Mar;36(2):115-24. doi: 10.1016/j.jaut.2010.12.003. Epub 2011 Jan 22.

20.

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Remington GM, Treadaway K, Frohman T, Salter A, Stüve O, Racke MK, Hawker K, Agosta F, Sormani MP, Filippi M, Frohman EM.

Ther Adv Neurol Disord. 2010 Jan;3(1):3-13. doi: 10.1177/1756285609355851.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk